within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR09_EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat;
model EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat 
   extends Pharmacolibrary.Drugs.ATC.J.J05AR09;

  annotation(Documentation(
    info ="<html><body><p>This fixed-dose combination consists of emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), elvitegravir (an integrase inhibitor), and cobicistat (a pharmacokinetic enhancer/booster). The combination is used as a complete regimen for the treatment of HIV-1 infection in adults and adolescents. It is widely approved and used as a single-tablet regimen to improve adherence and reduce pill burden in HIV therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters have been reported in healthy adult subjects after oral administration of the fixed-dose combination tablet (once daily). PK parameters reflect values at steady-state.</p><h4>References</h4><ol><li><p>Natukunda, E, et al., &amp; Rhee, MS (2017). Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. <i>The Lancet. Child &amp; adolescent health</i> 1(1) 27–34. DOI:<a href=&quot;https://doi.org/10.1016/S2352-4642(17)30009-3&quot;>10.1016/S2352-4642(17)30009-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30169223/&quot;>https://pubmed.ncbi.nlm.nih.gov/30169223</a></p></li><li><p>Feng, HP, et al., &amp; Yeh, WW (2019). Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants. <i>Clinical pharmacology in drug development</i> 8(7) 952–961. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.702&quot;>10.1002/cpdd.702</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31173673/&quot;>https://pubmed.ncbi.nlm.nih.gov/31173673</a></p></li><li><p>Yamada, H, et al., &amp; Irie, S (2018). Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. <i>Clinical pharmacology in drug development</i> 7(2) 132–142. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.365&quot;>10.1002/cpdd.365</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28581645/&quot;>https://pubmed.ncbi.nlm.nih.gov/28581645</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat;
